Avid Bioservices Inc (CDMO)

[cjgaddy]

Last 3 PPHM/Form4’s for Lias/Bamforth/Walsh

10-24-17 FORM4’S FOR OPTIONS GRANTED:
...(both vesting monthly over 36mos. Beg. 11-20-17)
1. Mark R. Bamforth 75,000sh. @$3.88 http://tinyurl.com/ybfm5tfe (BOD #6)
2. Patrick D. Walsh 75,000sh. @$4.08 http://tinyurl.com/y9hf7d8a (BOD #7)

9-27-17 FORM4 FOR OPTIONS GRANTED:
...(vesting in 4 equal annual installments beg. 9-25-18)
Roger J. Lias 150,000sh. @$3.19 http://tinyurl.com/yavfa6w7 (CEO/Avid, BOD #5)

= = = = = = = = = = = = = = = = =
10-24-17: http://tinyurl.com/yd3mtowk
Large-Shareholders(35%), RONIN-PPHM HISTORY, Upcoming Events: updated 10-24-17 w/PPHM’s PR announcing that Patrick Walsh is joining the BOD of both Peregrine & Avid (7th member), “An Industry Veteran with 30+yrs Experience Leading Successful CDMO Organizations”.
NOTE:
RONIN/SWIM’s 8-29-17 PRELIM. Proxy Statement (14A) and PPHM’s 8-28-17 Amended 10-K were added previously, as well as Ronin’s 10-10-17 PR announcing they will nominate James J. Egan as their 4th BOD candidate, Ronin’s Roger Farley establishing a stake of 110,763sh. Oct13-16, and PPHM’s 10-19-17 stating that, “Peregrine is transitioning from an R&D focused business to a pure play CDMO”, and “is pursuing to license or sell its proprietary R&D assets, including its lead immunotherapy candidate, bavituximab...”, and PPHM’s 10-23-17 giving the compensation details for new BOD member Mark R. Bamforth: $55000/yr + $15000/committee + $2000/meeting – plus, “The Compensation Committee expects that existing non-emp. directors will transition to the new (“recently amended”) non-emp. director compensation pgm over a period of time.”
. . .